Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05348577 · ClinicalTrials.gov registry record · Phase 3

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 3 study of Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,035
Enrollment target
20
Study locations

NCT05348577 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,035 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05348577, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,035 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

Conditions Studied

Prostate Cancer

Interventions

  • OTHER placebo
  • DRUG docetaxel
  • DRUG capivasertib

Study Locations (20)

California

  • Research Site - Beverly Hills
  • Research Site - Cerritos
  • Research Site - Fresno
  • Research Site - Los Angeles
  • Research Site - Sacramento
  • Research Site - San Francisco
  • Research Site - Santa Barbara
  • Research Site - Santa Monica
  • Research Site - Santa Rosa

Colorado

  • Research Site - Aurora
  • Research Site - Lakewood
  • Research Site - Littleton

Maryland

  • Research Site - Baltimore
  • Research Site - Baltimore

Minnesota

  • Research Site - Minneapolis
  • Research Site - Minneapolis

New York

  • Research Site - Albany
  • Research Site - The Bronx

Arizona

  • Research Site - Yuma

New Jersey

  • Research Site - Hackensack

Trial Details

FieldValue
Enrollment Target 1,035 participants
Start Date 2022-03-25
Est. Completion 2026-03-04
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05348577

The ClinicalTrials.gov registry entry for NCT05348577 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,035 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT05348577 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Maryland.

Frequently Asked Questions

What is clinical trial NCT05348577 about?

NCT05348577 is a clinical study titled "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)". This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The int...

What is the current status of trial NCT05348577?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2022-03-25. Estimated completion is 2026-03-04.

What conditions does trial NCT05348577 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05348577?

The interventions under investigation include: placebo (OTHER), docetaxel (DRUG), capivasertib (DRUG).

Who is sponsoring clinical trial NCT05348577?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05348577 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.